Susan G. Komen New England grants more than $50K to three VT nonprofits

REGION – Susan G. Komen New England, the local affiliate of Susan G. Komen, the world’s largest network of breast cancer survivors and advocates, has granted more than $50,000 to three Vermont nonprofits through its Community Breast Health grants.

Komen New England annually awards funds through its competitive grants program, which supports local nonprofits in providing services to under-and-uninsured families facing breast cancer.

Vermont grant recipients include: Cancer Patient Support Foundation, cancer patient support program emergency fund; Central Vermont Medical Center, affordable breast screening in Central Vermont; and Southwestern Vermont Health Care Foundation; Bennington County access and navigation.

“These grants will help us reach the bold goal recently announced by Susan G. Komen to reduce the current number of breast cancer deaths in the U.S. by 50 percent by 2026,” said Lori van Dam, Komen New England CEO. “Up to one-third of women who are currently dying could be saved without any new medical breakthroughs. The programs we fund help overcome barriers to screening and treatment so all our neighbors have the same opportunities to access the care they need.”

Nearly $400,000 in grants was awarded to 10 nonprofits in Connecticut, Massachusetts, Maine, New Hampshire, and Vermont.

“We are deeply committed to providing funding for critical local breast cancer services,” said van Dam.

Organizations interested in applying for grants for 2019-2020 are encouraged to visit

Registration is open for the Vermont 2018 Susan G. Komen Race for the Cure, Saturday, July 21, at Riley Rink, Hunter Park, Manchester Center.

“We invite runners and walkers of all ages to participate in the world’s largest fundraising event for breast cancer,” said van Dam. “Net proceeds raised through the Race for Cure stay in our community to fund a variety of programs, including screenings, diagnosis and treatment services and patient navigation. They also support our national research priorities, including new early detection technologies and treatments for metastatic breast cancer.”

For more information, call 508-366-1945 or visit

Related Post

Back To Top